A Study to Evaluate Magnetic Resonance Spectroscopy Diagnosis and Follow-up of IDH-mutant Glioma

Overview

About this study

The purpose of this study is to develop an MRS-based measurement of 2-HG that is reliable, and to assess the reproducibility of the method(s) above on a cohort of patients with IDH mutant low grade gliomas.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

Adult patients (age >= 18 years old).
Suspected WHO grade II or III infiltrating glioma based on standard MR imaging.
No previous tumor treatment or surgery.
Surgery for definitive diagnosis anticipated to occur within 3 months of study imaging.

Exclusion Criteria:

Inability to undergo MR imaging for any reason (claustrophobia, habitus, implanted devices, etc.).
Previous cranial surgical operations if metallic plates or grafts are near the area of tumor.
Predominantly ring-enhancing disease on anatomic MR.
Pregnancy.

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location	Status
Rochester, Minn. Mayo Clinic principal investigator John Port, M.D., Ph.D.	Closed for enrollment

Mayo Clinic Location

Status

Rochester, Minn.

Mayo Clinic principal investigator

John Port, M.D., Ph.D.

Closed for enrollment

More information

Publications

Publications are currently not available

Clinical Trials